MINI-FUTURE LONG - BASILEA PHARMA Share Price

Certificat

XBSLGU

CH1316787071

Real-time Bid/Ask 08:19:54 03/07/2024 BST
0.47 CHF / 0.48 CHF +1.06% Intraday chart for MINI-FUTURE LONG - BASILEA PHARMA
1 month-29.85%
3 months+9.30%
Date Price Change
02/07/24 0.47 -4.08%
28/06/24 0.49 -5.77%
27/06/24 0.52 -1.89%

Delayed Quote Swiss Exchange

Last update July 02, 2024 at 04:20 pm

More quotes

Static data

Product typeKnock-Out con Stop Loss
Buy / SellCALL
Underlying BASILEA PHARMACEUTICA AG
Issuer UBS
XBSLGU
ISINCH1316787071
Date issued 16/01/2024
Strike 27.24 CHF
Maturity Unlimited
Parity 25 : 1
Emission price 0.34 CHF
Emission volume N/A
Settlement Por diferencias
Currency CHF

Technical Indicators

Highest since issue 0.7 CHF
Lowest since issue 0.24 CHF
Spread 0.01 CHF
Spread %2.08%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Sector
-
More about the company

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Basilea Pharmaceutica AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
38.75 CHF
Average target price
71.2 CHF
Spread / Average Target
+83.74%
Consensus
  1. Stock Market
  2. Certificates
  3. XBSLGU Certificat